共 28 条
Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease
被引:90
作者:
Lai, MK
Tsang, SW
Alder, JT
Keene, J
Hope, T
Esiri, MM
Francis, PT
Chen, CP
机构:
[1] Singapore Gen Hosp, Natl Inst Neurosci, Neurodegenerat Dis Program, Singapore 169608, Singapore
[2] Singapore Gen Hosp, Dept Clin Res, Dementia Res Lab, Singapore 169608, Singapore
[3] Kings Coll London, GKT Sch Biomed Sci, Wolfson Ctr Age Related Dis, Neurodegenerat & Clin Trials Grp, London SE1 1UL, England
[4] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England
[5] Univ Oxford, Radcliffe Infirm, Dept Clin Neurol & Neuropathol, Oxford OX2 6HE, England
基金:
英国惠康基金;
英国医学研究理事会;
关键词:
Alzheimer's disease;
serotonin receptors;
neocortex;
cognition;
D O I:
10.1007/s00213-004-2077-2
中图分类号:
Q189 [神经科学];
学科分类号:
071006 ;
摘要:
Rationale: Previous studies have demonstrated reductions of serotonin 5-HT2A receptors in the neocortex of Alzheimer's disease ( AD) patients. However, it is unclear whether such losses play a role in the cognitive decline of AD. Objectives: To correlate neocortical 5-HT2A receptor alterations with cognitive decline in AD. Methods: Postmortem frontal and temporal cortical 5-HT2A receptors were measured by [H-3] ketanserin binding in aged controls as well as in a cohort of AD patients who had been longitudinally assessed for cognitive decline and behavioral symptoms. Results: 5-HT2A receptor densities in both regions were reduced in severely demented AD patients compared to age-matched controls. In the temporal cortex, this reduction also correlated with the rate of decline of Mini-Mental State Examination (MMSE) scores. The association between 5-HT2A receptor loss and cognitive decline was independent of the effects of choline acetyltransferase ( ChAT) activity and presence of behavioral symptoms. Conclusions: Our data suggest that loss of neocortical 5-HT2A receptors may predict for faster cognitive decline in AD, and point to serotomimetics as potentially useful adjuvants to cholinergic replacement therapies.
引用
收藏
页码:673 / 677
页数:5
相关论文